Vestal Point Capital’s Neurocrine Biosciences NBIX Stock Holding History

Vestal Point Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$165M	Buy	+1,250,000	New	+$166M	4.6%	4
2025 Q3	–	Sell	-30,000	Closed	-$3.77M	–	90
2025 Q2	$3.77M	Buy	+30,000	New	+$3.44M	0.2%	58
2024 Q2	–	Sell	-710,000	Closed	-$97.9M	–	73
2024 Q1	$97.9M	Sell	710,000 -90,000	-11%	-$12.3M	8.1%	3
2023 Q4	$105M	Buy	+800,000	New	+$92.1M	11.17%	1

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's NBIX Position: Q1 2026 in Review

Vestal Point Capital opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 1,250,000 shares worth $165M. The stake represents 4.6% of the portfolio and ranks #4 among its holdings. This is a return to the name: Vestal Point Capital previously reported a position in NBIX as recently as Q2 2025.

Vestal Point Capital first reported a position in NBIX in Q4 2023 and has held it in 4 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Vestal Point Capital held 1,250,000 shares of Neurocrine Biosciences worth $165M as of Q1 2026.
Neurocrine Biosciences was a new Vestal Point Capital position in Q1 2026.
Neurocrine Biosciences made up 4.6% of Vestal Point Capital's portfolio in Q1 2026, its #4 holding.
Vestal Point Capital first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 4 quarters since.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.